NY1DD mice have baseline pulmonary leukocytosis that is transiently decreased by injecting mice with anti-CD1d antibodies
| Cells, 105 . | (a) C57BL/6 (n = 21) . | (b) NY1DD (n = 17) . | (c) P . | (d) NY1DD isotype (n = 10) . | (e) NY1DD 1 day after anti-CD1d (n = 10) . | (f) NY1DD 5 days after anti-CD1d (n = 5) . |
|---|---|---|---|---|---|---|
| PMNs | 0.19 (0.04) | 1.32 (0.33) | .003 | 1.53 (0.14) | 0.84 (0.12)* | 1.51 (0.31)† |
| CD4 | 2.10 (0.28) | 3.12 (0.37) | .031 | 2.59 (0.28) | 1.04 (0.21)* | 3.87 (0.19)†‡ |
| CD8 | 1.40 (0.15) | 2.33 (0.32) | .008 | 2.06 (0.44) | 0.66 (0.18)* | 2.60 (0.27)† |
| NK | 2.25 (0.31) | 4.45 (0.77) | .007 | 4.64 (0.38) | 1.50 (0.22)* | 2.36 (0.97)† |
| iNKT | 0.18 (0.02) | 0.43 (0.03) | < .001 | 0.38 (0.04) | 0.20 (0.05) | 0.65 (0.21)†‡ |
| Cells, 105 . | (a) C57BL/6 (n = 21) . | (b) NY1DD (n = 17) . | (c) P . | (d) NY1DD isotype (n = 10) . | (e) NY1DD 1 day after anti-CD1d (n = 10) . | (f) NY1DD 5 days after anti-CD1d (n = 5) . |
|---|---|---|---|---|---|---|
| PMNs | 0.19 (0.04) | 1.32 (0.33) | .003 | 1.53 (0.14) | 0.84 (0.12)* | 1.51 (0.31)† |
| CD4 | 2.10 (0.28) | 3.12 (0.37) | .031 | 2.59 (0.28) | 1.04 (0.21)* | 3.87 (0.19)†‡ |
| CD8 | 1.40 (0.15) | 2.33 (0.32) | .008 | 2.06 (0.44) | 0.66 (0.18)* | 2.60 (0.27)† |
| NK | 2.25 (0.31) | 4.45 (0.77) | .007 | 4.64 (0.38) | 1.50 (0.22)* | 2.36 (0.97)† |
| iNKT | 0.18 (0.02) | 0.43 (0.03) | < .001 | 0.38 (0.04) | 0.20 (0.05) | 0.65 (0.21)†‡ |
At baseline, NY1DD mice have significantly increased numbers of pulmonary leukocytes. Anti-CD1d was injected (10 μg/g/d; 2 days), and lungs were harvested either 1 day (columns d and e) or 5 days later (column f). P values (c) were calculated using an unpaired t test. Data represents mean (SEM). P values (f) were calculated by one-way ANOVA with Neuman-Keuls posttesting. P less than .05 was considered significant.
Column d versus column e.
Column e versus column f.
Column d versus column f.